Fawzi F. Abu Rous, MD
Dr. Fawzi Abu Rous is a medical oncologist at Henry Ford Health Care in Detroit, Michigan. He is a specialist in the care of patients diagnosed with lung cancer, malignant pleural mesothelioma, and other thoracic malignancies, and is dedicated to patient care that delivers the same level of compassion and attention that he would provide to his own family members.[1]
Dr. Abu Rous’ treatment approach centers on providing his patients with the knowledge and resources they need to make informed, empowered decisions about their own care. His clinical expertise relies on multidisciplinary expertise from his colleagues and innovative combinations of immunotherapy, targeted therapies, and antibody-drug conjugates.[1]
Education and Career
Dr. Abu Rous earned his medical degree at the University of Jordan Faculty of Medicine and then completed his internship and residency in Internal Medicine at the Michigan State University/Sparrow Hospital. While there, he was recognized as Outstanding Junior and Senior Resident, Outstanding Teaching Rsident, and Outstanding Resident in Hematology and Oncology. He then completed a fellowship in Hematology/Oncology specializing in the treatment of lung cancer at Henry Ford Health, where he worked under the mentorship of Dr. Shirish Gadgeel.[1]
Dr. Abu Rous has published several manuscripts and book chapters and presented abstracts at local and national medical conferences.
Research
Dr. Abu Rous is actively involved in research investigating better outcomes and tools to guide treatment decisions for lung cancer patients. He has secured funding from the ASCO Conquer Cancer Foundation in support of his clinical trials developing squamous cell carcinoma biomarkers. He also designs and leads clinical trials for lung cancer treatment, exploring innovative combinations including immunotherapy, targeted therapies, and antibody drug conjugates.[1]
His recent publications include:[2]
Challenges Faced by J-1 International Medical Graduates (IMGs) During COVID-19 Pandemic. Fawzi Abu Rous, Ivy Riano>; Cancer Investigation. 2023 Feb 14
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. Houssein Safa, Fawzi Abu Rous, Neel Belani, Hossein Borghaei, Shirish Gadgeel, Balazs Halmos>; Targeted Oncology. 2023 Jan 1
Lung Cancer Treatment Advances in 2022. Fawzi Abu Rous, Eric K Singhi, Arthi Sridhar, Muhammad Salman Faisal, Aakash Desai>;Cancer Investigation. 2023 Jan 1
